Dongwu Securities released a research report on April 26 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) the gonadotropin and diagnostic reagent sector grasped the impressive growth rate of mar

Dongwu Securities released a research report on April 26 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) the gonadotropin and diagnostic reagent sector grasped the impressive growth rate of market demand, and overall revenue and profit were in line with expectations; 2) they were optimistic about the accelerated implementation of high-end formulations and biopharmaceutical pipelines, and incremental products contributed to a peak sales of 6.5 billion yuan. (Mainichi Keizai Shimbun)

Zhitong Finance25minutes ago

Pearl Group (000513): Excellent performance in the field of promotion and diagnostic reagents, and steady overall profit

Key investment events: The company announced its results for the first quarter of 2024. In 24Q1, the company achieved revenue of 3.243 billion yuan (-4.99%, same as below) and net profit to mother of 608 million yuan (+4.45%).

東吳證券48minutes ago

Sinopharm is consistent (000028): Distribution is growing steadily, and retail growth is slowing down under a high base

Guide to this report: 2024Q1 distribution has maintained steady growth, and retail sales have declined due to the decline in high base growth, and the industry has contributed steady profits. With improvements in internal business quality and product restructuring, the company's net interest rate is expected to continue to rise. Key investment points: maintaining and increasing holdings

國泰君安18:51

Express News | Livou Group: The company obtained approval from the US FDA for injectable cetrorelix acetate

Breakings18:21

China Post Securities released a research report on April 26 stating that Hualan Biotech (002007.SZ) was given a purchase rating. The main reasons for the rating include: 1) The growth rate of blood products slowed down during the same period last year; 2

China Post Securities released a research report on April 26 stating that Hualan Biotech (002007.SZ) was given a purchase rating. The main reasons for the rating include: 1) The growth rate of blood products slowed down during the same period last year; 2) the first batch of influenza vaccines was issued in April. (Mainichi Keizai Shimbun)

Zhitong Finance18:02

BeiGene Releases “2023 Responsible Business and Sustainability” Report, Announces Global Progress

The 2023 annual report details the company's achievements in sustainability and future plans in Beijing, China; Cambridge, MA; and Basel, Switzerland, April 26, 2024/PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global oncology innovation company, today released the “2023 Responsible Business and Sustainability” report, which highlights the company's strategy, progress made with current goals, and how to achieve more in the future Positive new goals. In the report

PR Newswire18:00